Prevalence of Symptomatic Pelvic Floor Disorders in US Women by Nygaard, Ingrid
Prevalence of Symptomatic Pelvic Floor Disorders in US Women
Ingrid Nygaard, MD, MS,
Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City
Matthew D. Barber, MD, MHS,
Department of Obstetrics, Gynecology, and Women’s Health Institute and Cleveland Clinic,
Cleve-land, Ohio
Corresponding Author: Ingrid Nygaard, MD, MS, Department of Obstetrics and Gynecology, University of Utah School of Medicine,
30 N 1900 E, Salt Lake City, UT 84132-2209 (ingrid.nygaard@hsc.utah.edu).
The Pelvic Floor Disorders Network Members: Cleve-land Clinic, Cleveland, Ohio: Mathew D. Barber, MD, MHS, principal
investigator; Marie Fidela R. Paraiso, MD, co-investigator; Mark D. Walters, MD, co-investigator; J. Eric Jelovsek, MD, co-
investigator; Linda McElrath, RN, research nurse; Donel Murphy, RN, MSN, coordinator research nurse; Cheryl Williams, research
assistant; Duke University, Durham, North Carolina: Anthony G. Visco, MD, principal investigator; Jennifer Wu, MD, MPH, co-
investigator; Alison Weidner, MD, co-investigator; Cindy Amundsen, MD, co-investigator; Mary J. Loomis, RN, BSN, research
coordinator; Loyola University, Chicago, Illinois: Linda Brubaker, MD, MS, principal investigator; Kimberly Kenton, MD, MS,
investigator; MaryPat FitzGerald, MD, MS, investigator; Elizabeth Mueller, MD, MSME, investigator; Kathy Marchese, RN, study
coordinator; Mary Tulke, RN, study coordinator; University of Alabama at Birmingham: Holly E. Richter, PhD, MD, principal
investigator; R. Edward Varner, MD, co-investigator; Robert L. Holley, MD, co-investigator; Thomas L. Wheeler, MD, co-
investigator; Patricia S. Goode, MD, co-investigator; Kathryn L. Burgio, PhD, co-investigator; L. Keith Lloyd, MD, co-investigator;
Alayne D. Markland, DO, co-investigator; Velria Willis, RN, BSN, research coordinator; Nancy Saxon, BSN, research nurse clinician;
LaChele Ward, LPN, research specialist; Lisa S. Pair, CRNP; University of California, San Diego, and Kaiser, San Diego: Charles W.
Nager, MD, principal investigator; Shawn A. Menefee, MD, co-investigator; Emily Lukacz, MD, co-investigator; Karl M. Luber, MD,
co-investigator; Michael E. Albo, MD, co-investigator; Margie Kahn, MD, co-investigator; Lysa Woodall, RN, study coordinator;
Giselle Zazueta-Damian, study coordinator; University of Michigan, Ann Arbor: Morton B. Brown, PhD, co-investigator; Cathie
Spino, DSc, principal investigator; John T. Wei, MD, MS, co-principal investigator; Beverly Marchant, RN, BS, project manager;
Donna DiFranco, BS, clinical monitor; John O.L. DeLancey, MD, co-investigator; Dee Fenner, MD, co-investigator; Nancy K. Janz,
PhD, co-investigator; Wen Ye, PhD, and Zhen Chen, MS, statisticians; Yang Wang Casher, MS, database programmer; University of
Texas, Southwestern: Joseph Schaffer, MD, principal investigator; Clifford Wai, MD, co-investigator; Marlene Corton, MD, co-
investigator; Gary Lemack, MD, co-investigator; Kelly Moore, research coordinator; David Rahn, MD, co-investigator; Amanda
White, MD, co-investigator; Shanna Atnip, NP, Margaret Hull, NP, Pam Martinez, NP, Deborah Lawson, NP; University of Utah, Salt
Lake City: Ingrid Nygaard, MD, MS, principal investigator; Peggy Norton, MD, co-investigator; Linda Freeman, RN, research
coordinator; Jan Baker, NP; National Institutes of Health Project Scientist: Susan Meikle, MD, MSPH.
Additional Information: The National Centers for Health Statistics acquired the data, as they actually interviewed the patients;
therefore, 2005–2006 NHANES collected all data. However, Drs Nygaard, Meikle, and Whitehead and Ms Brody were responsible for
spearheading the effort to add the Pelvic Floor Disorders questions to NHANES, assisting with pilot testing of questions, and assisting
with training field workers on administering questions.
Author Contributions: Dr Spino had full access to all of the data in the study and takes responsibility for the integrity of the data and
the accuracy of the data analysis.
Study concept and design: Nygaard, Burgio, Meikle, Whitehead, Wu, Brody.
Acquisition of data: Nygaard, Meikle, Whitehead, Brody.
Analysis and interpretation of data: Nygaard, Barber, Kenton, Schaffer, Spino, Brody.
Drafting of the manuscript: Nygaard, Barber, Burgio, Kenton, Meikle, Schaffer, Spino, Whitehead, Wu.
Critical revision of the manuscript for important intellectual content: Nygaard, Barber, Burgio, Kenton, Meikle, Spino, Whitehead,
Wu, Brody.
Statistical analysis: Spino.
Administrative, technical, or material support: Nygaard, Brody.
Study supervision: Nygaard.
Financial Disclosures: Dr Barber reported receiving research support from American Medical Systems and Pfizer, and speaking fees
for American Medical Systems. Dr Burgio reported being a paid consultant for Pfizer, Astellas, GlaxoSmithKline, Eli Lilly, Ortho-
McNeil, Novartis, and Merck; and receiving research support from Pfizer and Alza. Dr Kenton reported receiving research support
from Pfizer. Dr Meikle, a National Institute of Child Health and Human Development (NICHD) employee, is the Pelvic Floor
Disorders Network project officer. Dr Schaffer reported receiving research support from Cook Medical Inc and speaking fees from
Astellas/GlaxoSmithKline. Dr Spino was employed by Pfizer until August 10, 2007. She has no ownership interests and no ongoing
financial relationship with Pfizer. Dr Whitehead reported receiving research support and being a paid consultant to McNeil
Pharmaceuticals (makers of Imodium). No other authors reported any financial disclosures.
NIH Public Access
Author Manuscript
JAMA. Author manuscript; available in PMC 2010 August 9.
Published in final edited form as:













Kathryn L. Burgio, PhD,
Department of Medicine, University of Alabama at Birmingham and Department of Veterans
Affairs, Birmingham, Alabama
Kimberly Kenton, MD, MS,
Departments of Obstetrics and Gynecology and Urology, Loyola University Chicago–Stritch
School of Medicine, Maywood, Illinois
Susan Meikle, MD, MSPH,
Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda,
Maryland
Joseph Schaffer, MD,
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center,
Dallas
Cathie Spino, DSc,
Department of Biostatistics and Biostatistics and Outcomes Research Core, University of
Michigan School of Public Health, Ann Arbor
William E. Whitehead, PhD,
Department of Internal Medicine, University of North Carolina School of Medicine, Chapel Hill
Jennifer Wu, MD, MPH, and
Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, North
Carolina
Debra J. Brody, MPH
National Centers for Health Statistics, Hyattsville, Maryland
for the Pelvic Floor Disorders Network
Abstract
Context—Pelvic floor disorders (urinary incontinence, fecal incontinence, and pelvic organ
prolapse) affect many women. No national prevalence estimates derived from the same
population-based sample exists for multiple pelvic floor disorders in women in the United States.
Objective—To provide national prevalence estimates of symptomatic pelvic floor disorders in
US women.
Design, Setting, and Participants—A cross-sectional analysis of 1961 nonpregnant women
(≥20 years) who participated in the 2005–2006 National Health and Nutrition Examination
Survey, a nationally representative survey of the US noninstitutionalized population. Women were
interviewed in their homes and then underwent standardized physical examinations in a mobile
examination center. Urinary incontinence (score of ≥3 on a validated incontinence severity index,
constituting moderate to severe leakage), fecal incontinence (at least monthly leakage of solid,
liquid, or mucous stool), and pelvic organ prolapse (seeing/feeling a bulge in or outside the
vagina) symptoms were assessed.
Main Outcome Measures—Weighted prevalence estimates of urinary incontinence, fecal
incontinence, and pelvic organ prolapse symptoms.
Results—The weighted prevalence of at least 1 pelvic floor disorder was 23.7% (95%
confidence interval [CI], 21.2%–26.2%), with 15.7% of women (95% CI, 13.2%–18.2%)
experiencing urinary incontinence, 9.0% of women (95% CI, 7.3%–10.7%) experiencing fecal
incontinence, and 2.9% of women (95% CI, 2.1%–3.7%) experiencing pelvic organ prolapse. The
proportion of women reporting at least 1 disorder increased incrementally with age, ranging from
9.7% (95% CI, 7.8%–11.7%) in women between ages 20 and 39 years to 49.7% (95% CI, 40.3%–
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59.1%) in those aged 80 years or older (P<.001), and parity (12.8% [95% CI, 9.0%–16.6%],
18.4% [95% CI, 12.9%–23.9%], 24.6% [95% CI, 19.5%–29.8%], and 32.4% [95% CI, 27.8%–
37.1%] for 0, 1, 2, and 3 or more deliveries, respectively; P<.001). Overweight and obese women
were more likely to report at least 1 pelvic floor disorder than normal weight women (26.3% [95%
CI, 21.7%–30.9%], 30.4% [95% CI, 25.8%–35.0%], and 15.1% [95% CI, 11.6%–18.7%],
respectively; P<.001). We detected no differences in prevalence by racial/ethnic group.
Conclusion—Pelvic floor disorders affect a substantial proportion of women and increase with
age.
Pelvic floor disorders include urinary incontinence, pelvic organ prolapse, fecal
incontinence, and other sensory and emptying abnormalities of the lower urinary and
gastrointestinal tracts. A regional study in the United States found that almost 10% of
women have surgery for urinary incontinence, pelvic organ prolapse, or both during their
lifetime, and 30% of those women have 2 or more surgical procedures.1 However, because
no single national population-based survey has assessed the prevalence of the 3 major pelvic
floor disorders in US women, the national burden related to these diseases remains
unknown.
Thus, in 2003, the Pelvic Floor Disorders Network (PFDN) submitted a proposal to add
questions about pelvic floor disorders to the 2005–2006 National Health and Nutrition
Examination Survey (NHANES). The PFDN, a clinical trials network of investigators from
7 clinical centers and a data coordinating center, is supported by the Eunice kennedy shriver
National Institute of Child Health and Human Development and the National Institutes of
Health Office of Research on Women’s Health. The primary goal of the PFDN is to improve
diagnosis, treatment, and prevention of pelvic floor disorders in women.
The goal of this research study is to provide prevalence estimates of symptomatic pelvic
floor disorders by demographic characteristics in nonpregnant women aged 20 years or older
between January 2005 and December 2006.
METHODS
The 2005–2006 NHANES Program
The NHANES program consists of cross-sectional, national health surveys conducted by the
National Centers for Health Statistics Centers for Disease Control and Prevention. Each
NHANES provides national estimates of health status of adults in the United States at the
time of the survey by selecting a nationally representative sample of the civilian,
noninstitutionalized US population, by using a complex, stratified, multistage, probability
cluster design. The 2005–2006 NHANES oversampled persons aged 60 years or older, and
black, Mexican American, and low-income white individuals to provide more reliable
estimates for these groups. The National Centers for Health Statistics Ethics Review Board
approved the protocol, and all participants provided written informed consent. This analysis
of NHANES data met criteria for exemption of human subjects research review by the
University of Utah Institutional Review Board.
Study Population
Participants were interviewed in their homes and then underwent standardized physical
examinations, including measured height and weight, in a mobile examination center.
Trained interviewers asked about symptoms of pelvic floor disorders and reproductive
history as part of a private interview in the mobile examination.
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Of 3440 women aged 20 years or older originally selected through a probability sampling
for the 2005–2006 NHANES survey, 2592 women (75.4%) agreed to participate and
completed the household interview and 2489 women (72.4%) agreed to participate in the
mobile examination center. Of these women, 236 (9.5%) were missing data on all 3 pelvic
floor outcomes. After eliminating 292 women who were currently pregnant, our final
analytic data set comprised 1961 women.
To define urinary incontinence, we used the validated 2-item incontinence severity index,
which correlates well with incontinence volume based on pad weights and incontinence
frequency obtained on bladder diaries.2,3 The incontinence severity index is based on
responses to frequency (<once per month, a few times a month, a few times a week, or every
day and/or night) and amount of leakage (drops, splashes, or more). By multiplication, an
index value of 1 to 12 is reached. Because many women report infrequent, nonbothersome
urinary leakage, we limited our case definition to moderate to severe incontinence defined as
a severity score of at least 3 on the incontinence severity index. This corresponds to at least
weekly leakage or monthly leakage of volumes more than just drops. We considered women
to be continent when the severity score was less than 3.
We defined fecal incontinence as at least monthly leakage of solid, liquid, or mucous stool,
determined by responses on the validated fecal incontinence severity index, which applies a
type × frequency matrix to obtain the patient’s perception of symptom severity.4,5 We did
not include leakage of flatus in our definition of fecal incontinence as it is frequently
reported but less bothersome.
We defined symptomatic pelvic organ prolapse as a positive response to the question, “Do
you experience bulging or something falling out you can see or feel in the vaginal area?”,
which was derived from the Pelvic Floor Distress Inventory.6 A positive response correlates
with the presence of a vaginal bulge on examination; however, the question has higher
specificity than sensitivity for pelvic organ prolapse based on examination.7 Prolapse
estimates using this question underreport the true prevalence of prolapse on examination.
Participants self-reported their race/ethnicity based on lists that included an open response.
In this analysis, a composite racial/ethnic variable was used to assess differences in pelvic
floor disorders among 4 racial/ethnic groups: (1) non-Hispanic white; (2) non-Hispanic
black; (3) Hispanic (composed mostly of Mexican Americans due to the oversampling); and
(4) other (Indian [American], Alaska Native, Native Hawaiian, Guamanian, Samoan, other
Pacific Islander, Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese, and other
Asian). Age was categorized in 20-year increments beginning with 20 years and ending with
80 years or more; education was categorized as less than high school, high school diploma
including General Education Development, and more than high school; the poverty income
ratio (an indicator of socioeconomic status that uses the ratio of income to the family’s
poverty threshold set by the US Census Bureau) was categorized as less than 1 (below the
poverty threshold), 1 to 2 (1–2×above the poverty threshold), and more than 2 (>2×above
the poverty threshold); body mass index (calculated as weight in kilograms divided by
height in meters squared) was categorized as less than 25.0 (underweight/normal weight),
25.0 to 29.9 (overweight), and 30.0 or more (obese); and parity (total number of vaginal and
cesarean deliveries) was categorized as 0, 1, 2, and 3 or more.
Statistical Analysis
Weighted prevalence estimates and 95% confidence intervals (CIs) were calculated by using
SAS version 9.1 (SAS Institute Inc, Cary, North Carolina), incorporating the design effect,
appropriate sample weights, stratification, and clustering of the complex NHANES sample
design. The sample weights adjust for unequal probabilities of selection and nonresponse.
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Estimates with relative standard errors of more than 30% were considered statistically
unreliable and are identified as such (Table). The Rao-Scott Modified χ2 test was used to test
the association between pelvic floor disorders outcome and demographic characteristics. P<.
05 was considered statistically significant.
RESULTS
Overall, 23.7% (95% CI, 21.2%–26.2%) of women had symptoms of at least 1 pelvic floor
disorder. Of these, 15.7% (95% CI, 13.2%–18.2%) experienced urinary incontinence, 9.0%
(95% CI, 7.3%–10.7%) experienced fecal incontinence, and 2.9% (95% CI, 2.1%–3.7%)
experienced symptomatic pelvic organ prolapse. The proportion of women that reported at
least 1 pelvic floor disorder increased with age (9.7% [95% CI, 7.8%–11.7%] in women
aged 20 to 39 years, 26.5% [95% CI, 23.0%–29.9%] in women aged 40 to 59 years, 36.8%
[95% CI, 32.0%–41.6%] in women aged 60 to 79 years, and 49.7% [95% CI, 40.3%–59.1%]
in women aged 80 years or older; P <.001). The Table shows the percentage of respondents
with each pelvic floor disorder by demographic characteristics. Other characteristics that
were significantly associated with at least 1 pelvic floor disorder were (1) family poverty
income ratio (20.8% [95% CI, 18.1%–23.5%] if >2-fold above the poverty threshold vs
28.8% [95% CI, 21.8%–35.7%] if below the poverty threshold and 29.7% [95% CI, 25.1%–
34.3%] if 1–2 × above the poverty threshold; P=.002); (2) body mass index (15.1% [95%
CI, 11.6%–18.7%] for underweight/normal weight, 26.3% [95% CI, 21.7%–30.9%] for
overweight, and 30.4% [95% CI, 25.8%–35.0%] for obese women; P<.001); and (3) parity
(12.8% [95% CI, 9.0%–16.6%] for nulliparous women vs 18.4% [95% CI, 12.9%–23.9%],
24.6% [95% CI, 19.5%–29.8%], and 32.4% [95% CI, 27.8%–37.1%] for those women with
1, 2, and ≥3 deliveries, respectively; P<.001). Race/ethnicity and education were not
significantly associated with having at least 1 pelvic floor disorder (P = .26 and P = .06,
respectively).
Similar patterns were observed in the analyses of each pelvic floor disorder separately,
except that the prevalence of pelvic organ prolapse was only 2.9%, and thus estimates of its
prevalence in subgroups were too small to be reliable.
COMMENT
These data represent the first nationwide, population-based estimates of the 3 primary pelvic
floor disorders in women in the United States derived from a single source. Nearly one-
quarter of all women and more than one-third of older women reported symptoms of at least
1 pelvic floor disorder. By 2030, more than one-fifth of women will be 65 years or older.8
As the population of older women increases, the national burden related to pelvic floor
disorders in terms of health care costs, lost productivity, and decreased quality of life will be
substantial. Furthermore, our prevalence estimates are likely underestimates for several
reasons: (1) they do not reflect symptoms of women who have undergone successful
treatment for pelvic floor disorders; (2) we used conservative definitions; and (3) symptom-
based diagnosis underestimates the true prevalence of pelvic organ prolapse diagnosed by
physical examination.
Other studies, including data from NHANES in earlier waves,9–13 concluded that between
25% and 75% of women have urinary incontinence, depending on how the condition is
defined. Higher rates represent a symptom of occasional leakage, while lower rates are more
likely to represent a disease. We limited our definition to those women with moderate to
severe leakage to better reflect the population of women more likely to seek treatment.
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Similarly, published estimates of the prevalence of fecal incontinence in the community
range widely, from 2.2%14 up to 24%.15–18 As with urinary incontinence, differences in
prevalence estimates are explained in part by differences in case definition, with some
studies including involuntary loss of flatus in the definition and other studies limiting the
definition to loss of stool or mucus.
Population-based epidemiological studies of pelvic organ prolapse are rare, despite the fact
that it is a common indication for gynecologic surgery in older women. A major impediment
to population-based studies is the requirement of an examination to assess vaginal support.
Several studies,19–21 including our study, avoided this limitation by screening for prolapse
based on the presence of prolapse-related symptoms rather than examination. The symptom
most strongly correlated with the presence of advanced pelvic organ prolapse is “seeing” or
“feeling” a vaginal bulge.22–25 There is no clear consensus about what level of prolapse
represents a variation of normal uterovaginal support and what represents disease, although
there is growing consensus that prolapse beyond the hymen is more likely to be clinically
significant.22,25 Up to 75% of women presenting for routine gynecological care demonstrate
some prolapse, and 3% to 6% have descent beyond the hymen.26,27 The specificity of
vaginal bulge symptoms for predicting prolapse beyond the hymen is high in low-prevalence
populations (99%–100%); however, the sensitivity is low (16%–35%), because some
women with even advanced prolapse deny symptoms.7,25
Thus, prolapse prevalence in studies using symptom-based screening such as this one
underestimate the true prevalence of anatomic disease. However, because women typically
do not seek care for prolapse until symptoms develop and physicians generally do not offer
surgical treatment until symptoms become bothersome, symptom-based prevalence
estimates likely represent the best estimate of disease burden on the population.
The finding that both urinary and fecal incontinence increase with age is consistent with the
epidemiological literature.28–30 The few studies available show that apical, anterior, and
posterior vaginal wall prolapse also increases with advancing age.31–33 The relationship
between pelvic floor disorders and age is usually attributed to age-related connective tissue
and neuromuscular changes and to comorbidities, such as obesity, pulmonary disease, and
diabetes, that occur more commonly among older adults.
Consistent with prior studies, these data demonstrate a significant association between
childbirth and pelvic floor disorders. In the Oxford Family Planning Study,33 women with 2
deliveries were substantially more likely to have surgery for prolapse compared with women
with no delivery. In a cross-sectional study of Norwegian women, compared with women
with no deliveries,34 the effect of 2 or more deliveries on urinary incontinence was greatest
in younger women aged 20 to 34 years (relative risk [RR], 2.8; 95% CI, 2.3–3.3), decreased
among women aged 35 to 64 years (RR, 2.0; 95% CI, 1.6–2.3), and then, consistent with
other literature, was not associated with urinary incontinence in women older than 65 years.
The association between fecal incontinence and parity is inconsistent.35,36 However, the fact
that more than 1 in 8 nulliparous women in the 2005–2006 NHANES reported at least 1
symptomatic pelvic floor disorder demonstrates the multifactorial nature of these conditions.
In contrast with several other large studies in which white women had a higher prevalence of
urinary incontinence and pelvic organ prolapse than did black or Hispanic women,11,37–40
we found no difference in prevalence in comparisons of black, non-Hispanic white, or
Hispanic women. We did not categorize urinary incontinence by subtype (stress or urge) in
this analysis, which may account for this difference. A recent analysis using earlier
NHANES data (2001–2004) found a higher prevalence of stress urinary incontinence in
white and Mexican American women than black women, but no differences in other
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incontinence subtypes.41 Although national hospital discharge statistics show that black
women have lower rates of prolapse surgery than white women,41 this difference cannot be
attributed to just race. Many factors, including access to care, contribute to the decision to
undergo surgery, and therefore to surgical prevalence rates. Because we have no information
about treatment for pelvic floor disorders, we cannot comment on whether treatment varies
by race/ethnicity in our sample. Although Hispanic women were less likely than white or
black women to report fecal incontinence in our study, other studies found no such
difference in community-dwelling adults.15,17 Further research is needed to better
characterize racial and ethnic variations in pelvic floor disorders and to understand why such
differences exist. In addition, although the sample sizes were adequate to describe
prevalence rates by demographic characteristics, they were too small to provide meaningful
estimates of adjusted risk factors, including the effect of delivery type on pelvic floor
disorders. Additional years of data will allow for these analyses.
In conclusion, pelvic floor disorders affect a substantial proportion of women and increase
with age. Indeed, in a health maintenance organization, older women generated 10 times the
number of consults per 1000 women-years for treatment of pelvic floor disorders than did
younger women.42 Given the burden pelvic floor disorders place on US women and the
health care system, research is needed to further understand their pathophysiology,
prevention, and treatment.
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